Arvinas (ARVN) Capital Expenditures Growth (1y) (2018 - 2026)

Arvinas (ARVN) Capital Expenditures Growth (1y) (2018 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Capex Growth (1y) (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn - 38.18%
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn - -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn -27.93%
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn 227.76%
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn 0.57%
7 Belite Bio 62.72 Bn 62.72 Bn - -
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn -
9 Revolution Medicines 37.35 Bn 37.35 Bn - -
10 Arvinas 529.92 Mn -84.98 Mn - 225.00%

Historic Data

Download Data
DateValue
Mar 31, 2026 225.00%
Dec 31, 2025 -566.67%
Sep 30, 2025 -85.71%
Jun 30, 2025 50.00%
Dec 31, 2024 200.00%
Sep 30, 2024 -36.36%
Jun 30, 2024 33.33%
Dec 31, 2023 150.00%
Sep 30, 2023 650.00%
Jun 30, 2023 137.50%
Mar 31, 2023 -47.62%
Dec 31, 2022 -150.00%
Sep 30, 2022 85.71%
Jun 30, 2022 -420.00%
Mar 31, 2022 110.00%
Dec 31, 2021 -92.89%
Sep 30, 2021 41.86%
Jun 30, 2021 -72.59%
Mar 31, 2021 -26.59%
Dec 31, 2020 232.12%